CRBU
Caribou Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$205.26M
P/E Ratio
—
EPS
$-1.59
Beta
2.46
52W High
$3.54
52W Low
$0.73
50-Day MA
$1.95
200-Day MA
$1.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Caribou Biosciences Inc
Caribou Biosciences Inc. is a pioneering biotechnology company leveraging advanced CRISPR technology to create transformative therapies for genetic disorders and oncology. With a robust pipeline of innovative product candidates, the company is dedicated to addressing significant unmet medical needs and enhancing the landscape of precision medicine. Caribou's strategic collaborations and focus on proprietary genome-editing solutions underscore its potential to redefine treatment approaches and deliver substantial benefits to patients, positioning it as a leader in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $11.16M |
| Gross Profit (TTM) | $-96.36M |
| EBITDA | $-130.27M |
| Operating Margin | -722.00% |
| Return on Equity | -79.00% |
| Return on Assets | -34.30% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $1.28 |
| Price-to-Book | 1.68 |
| Price-to-Sales (TTM) | 18.39 |
| EV/Revenue | 8.35 |
| EV/EBITDA | -36.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 89.70% |
| Shares Outstanding | $98.68M |
| Float | $92.27M |
| % Insiders | 8.96% |
| % Institutions | 36.84% |
Historical Volatility
HV 10-Day
66.42%
HV 20-Day
66.77%
HV 30-Day
69.81%
HV 60-Day
76.84%
HV Rank
20.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($11.12 target)
1
Strong Buy7
BuyData last updated: 4/29/2026